MBio partners with industry, government and academia to develop unique, high-value portable technology solutions for a diverse set of applications in point-of-care diagnostics. 


MBio’s commercial partnerships are matched to partner needs. Typical arrangements include initial funded feasibility programs followed by more comprehensive product development and manufacturing supply agreements. In addition to providing instrumentation engineering services around the MBio core LightDeck® technology, the company offers partners extensive assay development expertise. 


In addition to migrating partner assays to the MBio platform, the MBio team can develop novel assays, unique assay workflows and product stabilization/shelf life strategies. All of this development is supported by a pilot-scale cartridge manufacturing facility. Although some partnerships are confidential, below are a few examples of ongoing programs:


Point-of-care diagnostics for companion animals


MBio has an exclusive veterinary partnership with Heska. Through innovation, invention, and strategic partnerships with worldwide leaders in diagnostics and treatments, Heska provides the benefits of latest generation technologies to pet healthcare providers. Heska’s range of complete blood diagnostic solutions include Chemistry, Hematology, Blood Gas & Electrolytes, Immunodiagnostics, Heartworåm, and other blood testing. Treatments and testing include Immunotherapy and complete Allergy solutions.

MBio is excited to be working with the Heska team to develop the next generation of rapid, low-cost, point-of-care diagnostics for companion animals.

Brava diagnostics

Transforming acute care diagnostics


Brava Diagnostics is developing acute care diagnostic products based on the MBio Diagnostics rapid testing platform. Our first applications will address unmet needs for assessment of chest pain and shortness of breath in the emergency department. Follow-on applications include diagnosis, staging and monitoring sepsis, the most expensive disease treated by hospitals.

Our multiplex technology enables rapid, quantitative measurement of very low concentrations of  proteins from whole blood.


Contributing global health and viral disease expertise


MBio Diagnostics has developed a longstanding collaboration with a team of world class clinical infectious disease experts at the University of California, San Diego (UCSD). Dr. Robert Schooley is a globally-recognized AIDS and viral disease expert and is Head of the Division of Infectious Diseases, Executive Vice Chairman of the UCSD Department of Medicine and Associate Director of the UCSD Center for AIDS Research. Dr. Constance Benson is Professor of Medicine and Director of the UCSD Antiviral Research Center (AVRC) and served as Chair of the Executive Committee of the NIH/NIAID AIDS Clinical Trials Group (ACTG) from 2002-2010. 

MBio Diagnostics and the UCSD clinical team have several ongoing research collaborations, including multiple programs funded by the NIH. UCSD and the Antiviral Research Center in San Diego serve as clinical evaluation sites of various MBio assays and devices. MBio Diagnostics also benefits from the global network of infectious disease researchers and sites coordinated by Drs. Schooley and Benson.

MBio – Ireland Partnerships


MBio has longstanding collaborations with preeminent laboratories in both Northern Ireland and the Republic of Ireland. The Institute for Global Food Security (IGFS) at Queen’s University, Belfast, Northern Ireland is a leader in toxin detection strategies. IGFS scientists have been working with the MBio system for several years, developing innovative multiplexed immunoassays that deliver extraordinary levels of sensitivity for toxin detection (see the MBio Publications page). MBio’s network also includes the partner institution of Dublin City University. This work continues to appear in high impact scientific journals and the tests are now entering a commercialization phase.